The move from preclinical work into first-in-human (FIH) studies changes what a bioanalytical method needs to do. While the chemistry behind a preclinical assay may be sound, the realities encountered in clinical studies often shift...
Collaboration brings together complementary large- and small-molecule bioanalytical expertise to provide a coordinated solution for complex drug development programs, including antibody-drug conjugates [Moscow, Idaho] — Oct 26, 2026...
Developing a bioanalytical method, to then be validated for animal models, that meets regulatory expectations is only one part of preparing an investigational new drug (IND) application. Regulators necessarily ultimately evaluate the...
As drug development programs advance toward and proceed into clinical studies, they often expand across multiple sample collection sites. This accelerates enrollment, building a far larger data set than a single early operation site could...
Matrix effects remain one of the most persistent technical challenges in LC-MS/MS bioanalysis, particularly in programs that require analysis across multiple biological samples such as plasma, tissue, and cerebrospinal fluid (CSF). Matrix...
Sponsors rarely transition to a new bioanalytical CRO because they want to. More often, the decision follows a triggering event that raises concerns about data quality, operational performance, regulatory readiness, or a laboratory's...
As organizations approach IND submission, the quality and reliability of bioanalytical data become central to regulatory evaluation. Among the most critical components of this data package is LC-MS/MS method validation, which underpins the...
To our Alturas Partners, Clients and Friends, Happy New Year! As we enter 2025, our 25th year in business, I want to take a moment to reflect on what has been an incredible 2024 and to express my heartfelt gratitude for the trust and...
Alturas Analytics Joins Historic Polaris Dawn Mission Moscow, Idaho—October 18, 2024—Alturas Analytics is excited to announce its participation in the groundbreaking Polaris Dawn mission, which launched on September 10, 2024. This...
Alturas Analytics, Inc., specializing in LC-MS/MS and GC-MS/MS bioanalysis and a leading provider of pharmaceutical development solutions, is proud to announce the appointment of Erik Burns as Chief Marketing and Business Strategy...
